Navigation Links
LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
Date:2/25/2008

TORRANCE Combined hormone therapy appears to increase the risk that women will have abnormal mammograms and breast biopsies, and it may decrease the effectiveness of both methods for detecting breast cancer, according to a report in the Feb. 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Rowan T. Chlebowski, M.D., Ph.D., a lead investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), was the lead author of the report. He and his colleagues studied 16,608 post-menopausal women who participated in the Womens Health Initiative (WHI) clinical trial, a 15-year study that began in 1993.

The research team examined the effect of combined hormone therapy on breast cancer detection over five years and found it resulted in more than one in 10 women having otherwise avoidable mammogram abnormalities and one in 25 women having breast biopsies. Combined hormone therapy also compromised the diagnostic performance of mammograms and breast biopsies.

These findings represent a concern for post-menopausal women who are considering hormone therapy, said Dr. Chlebowski. They should take the results of this study into consideration and consult with their physicians before undergoing even short-term hormone therapy.

The study examined the use of conjugated equine estrogens plus medroxyprogesterone acetate for approximately five years. A total of 8,506 women were randomly assigned to receive a combination of estrogen (0.625 milligrams of conjugated equine estrogens per day) plus progesterone (2.5 milligrams of medroxyprogesterone acetate per day), while 8,102 took a placebo. Each woman received a mammogram and breast examination yearly, with biopsies performed based on physicians clinical judgment.

During the 5.6 years of the study, 199 women in the combined hormone group and 150 women in the placebo group developed breast cancer. Mammograms with abnormal results were more common among women taking hormones than among women taking placebos: 35 percent vs. 23 percent.

Women taking hormones had a 4 percent greater risk of having a mammogram with abnormalities after one year and an 11 percent greater risk after five years.

Breast biopsies also were more common among women taking combined hormone therapy than among those taking placebos: 10 percent vs. 6.1 percent.

After discontinuation of combined hormone therapy, the adverse effects on mammogram and breast biopsy performance were seen even in younger women in the fifth decade of life, so the finding may impact women just entering menopause as well, said Dr. Chlebowski.

The study found the adverse effect of combined hormone therapy on mammograms modulated but remained significantly different from that of placebo for at least 12 months, according to the studys authors.


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. BioMed Realty Trust Joint Venture Enters Into New $245 Million Construction Loan and Extends Term of Existing Loan Facility
2. Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science
3. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
4. Lung Cancer Alliance Urges Inclusion of $5 Billion for Biomedical Research in Economic Stimulus Package
5. BioMed Central bolsters radiology image collection
6. New nanotube findings by Stanford researchers give boost to potential biomedical applications
7. American Red Cross Announces New Leader for Biomedical Services
8. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
9. BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends
10. LA BioMed researchers find few emergency rooms fully equipped for pediatric patients
11. LA BioMed research finds simpler way to assess breast cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation ... trial has been life-saving as she has been on the trial for more ... diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a year later ...
(Date:1/20/2017)... ... 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: a unique ... Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of ... interacting with countless women who had little knowledge of the female characters portrayed in ...
(Date:1/20/2017)... ... ... You”: a fine examination of how God handles sin, including how to let go ... Miller, who, for over ten long years has been waiting to release this powerful insight ... he has been serving the Lord for over twenty years, and he has been preaching ...
(Date:1/20/2017)... ... ... and enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” is ... a devoted woman of faith. , “Becoming a parent changes you. In my case, ... for years, but actually doing it might have been a while in coming if it ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “God's Miracle Man: ... All Odds” is the creation of published author, Keith C. A. Tucker, son of ... Christian Fellowship World Outreach pastured by Reverend Mark Hardy , “While sitting up in ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017 The U.S. Food and Drug ... Idiopathic Constipation (CIC) in adult patients. "No ... disorders," said Julie Beitz , M.D., director of the ... Drug Evaluation and Research. "With the availability of new therapies, ... for their condition." ...
(Date:1/19/2017)... 2017 Many patients don,t realize that they ... a pharmacy just a few blocks away charges only ... problem Medicationdiscountcard.com has created a price comparison ... much their medication will cost at most nearby pharmacies. ... Medicationdiscountcard.com takes all of the ...
(Date:1/19/2017)... , Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... and TomoTherapy® Systems continue to set the bar for ... highest composite overall user satisfaction rating among radiation treatment ... 2016 MD Buyline Market Intelligence Briefing™. The most recent ... composite ratings among industry peers for 11 of the ...
Breaking Medicine Technology: